HeyJaredAbdul Rahman
- Indexed articles, last 90 days
- 213
- Latest publication
- Sep 28, 2026
- Outlet visibility, for yahoo.com
- Top 1K sites
- Earliest in this view
- Jul 3, 2026
Latest articles
McDonald’s (MCD): Letâs Begin With a Smile (opens the original)
Read excerpt
McDonald’s Corporation (NYSE:MCD) has spent years trying to make its restaurants faster and more convenient. Pushing app ordering, self-service technology, and loyalty programs has been a major part of that strategy. But convenience is only part of the story. The bigger question is whether better restaurant economics can drive repeat visits and faster growth. We recently explored that opportunity in Can McDonald’s Turn Better Restaurant Economics into Faster Growth? But the company has realized
Lennar (LEN)âs Q3 Results Show the Cost of Protecting Home Sales (opens the original)
Read excerpt
Lennar Corporation (NYSE:LEN) delivered 20,840 homes in its fiscal Q3 ended August. That was within its own guidance of 20,500 to 21,500 deliveries but fell short of Wall Street expectations. That prompted StoneX to reiterate a Hold rating on Lennar after the results. The brokerage cited misses across deliveries, average selling price, revenue, and earnings. Don’t Miss: Jim Cramer Wasn’t Hopeful About This Major Homebuilding Stock Lennar’s Q3 home deliveries declined 3% to 20,840, and the averag
Meta Platforms (META): Are You Going to Buy the Promise? (opens the original)
Read excerpt
The promise is what Meta Platforms, Inc. (NASDAQ:META) can do with AI and the reward for investors. But the cost associated with the AI ambitions is steep, even for a company with deep pockets. But no pain, no gain. We’ve all heard that. Meta’s capital expenditures shot up to $31.1 billion in Q2, from $19.4 billion in the same quarter last year. The company generated only $784 million in free cash flow in the latest quarter, down sharply from $10.6 billion a year ago. All that is happening becau
Immunovant (IMVT): One Trial Failure Doesnât Break the Bull Case (opens the original)
Read excerpt
We all have bad days. Immunovant, Inc. (NASDAQ:IMVT) had its latest bad day on September 23 after a clinical-trial setback, sending the shares lower. The company reported that its Phase 2b proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus (CLE) failed to achieve the primary endpoint. The study failed to show a statistically significant difference versus placebo in the percent change from baseline in the CLASI-A score at Week 12. That prompted the company to discontinue develop
Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones (opens the original)
Read excerpt
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is building a business model that differs from that of many drug developers. Rather than relying on internally operated drug development programs, the company funds third-party programs and acquires royalty interests in exchange for economic rights in those assets. That model allows it to generate royalties and other income when the partnered products succeed. Ligand’s royalty strategy gained significant scale with its acquisition of XOMA Royalty
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1K sites
For yahoo.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.